tbuckley/cabot-search huggingface dataset:
Colonic obstruction following percutaneous endoscopic gastrostomy placement
Authors: H. Buluş, S. Köklü, A. Coşkun, N. Dereli, M. Akkoca
Journal: Endoscopy (2012)

A 64-year old man with a history of chronic obstructive pulmonary disease was admitted via the emergency clinic with respiratory failure. He was intubated and hospitalized in the intensive care unit. Because of difficulty weaning him from mechanical ventilation, a tracheostomy was performed. On the 20th day of hospitalization, a percutaneous endoscopic gastrostomy (PEG) tube was inserted. Enteral feeding was initiated, but abdominal distention and vomiting occurred almost immediately. The PEG tube was found to be intact on an endoscopic examination, but abdominal computed tomography (CT) demonstrated that the PEG tube was pulling both the anterior wall of the stomach and the transverse colon up against the abdominal wall ([Fig. 1]). A laparotomy was performed, which showed that the total colonic obstruction was caused by the walls of the colon being pressed against each other because the PEG tube was passing through the lumen of the transverse colon. The tube was detached, and a primary repair and percutaneous jejunal tube insertion were performed. The patient died on the 5th day after surgery as a result of septicemia.
Abstract 2069: Combinatorial microRNA activity associated with breast cancer metastasis is revealed through computational analysis of target genes and pathways
Authors: Alan A. Dombkowski, Zakia Sultana, Hasan Jamil, Douglas Craig
Journal: Cancer Research (2010)

Abstract A recent report identified six microRNAs with repressed expression in highly metastatic MDA-MB-231 breast cancer cell derivatives (miRs 335, 126, 206, 122a, 199a*, and 489). Expression of all six miRs was consistently decreased in cells that produced aggressive lung and bone metastases, as compared to parental cells, indicating that metastatic colonization is exacerbated by the concurrent loss of multiple miRs from this set. With the hypothesis that target genes involved in metastatic progression are regulated by cooperative activity of these six microRNAs, we performed a computational analysis to identify transcripts having multiple binding sites targeted by the collective set of miRs. Using miR-AT!, a new web-based computational tool developed in our laboratory, we identified 767 target transcripts with multiple sites, and we characterized the biological processes and pathways associated with the target genes. Among cellular processes enriched with genes from this set are regulation of cell cycle, cytoskeleton organization, and regulation of cell adhesion. Importantly, perturbation of these processes was recently noted as a common feature among all metastatic tumors. We have identified subsets of the six miRs that are predicted to regulate the genes in each of these critical cellular processes. Additionally, we analyzed signaling pathways downstream of the collective set of target genes to identify key regulatory molecules where the networks converge. The top scoring nodes were cyclin D1 and c-myc, suggesting that dysregulation of target genes due to the collective loss of the microRNAs may have a focused effect on the activity of these two key genes. Access to miR-AT! is available at www.mir-at.org. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2069.
Free Speech, Chimpanzees, and Libel Law
Authors: LEO UZYCH
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Free Speech, Chimpanzees, and Libel Law Get access LEO UZYCH LEO UZYCH Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 21, 6 November 1991, Pages 1589–1590, https://doi.org/10.1093/jnci/83.21.1589-a Published: 06 November 1991
Abstract 54: Role of aldehyde dehydrogenase 1 in breast cancer stem cell survival
Authors: Min Zhang, Dale Hogan, Aramati Bindu Reddy, Kota Ramana, Satish Srivastava, Naseem H. Ansari
Journal: Cancer Research (2010)

Abstract Tumor initiation and progression are mainly driven by a small subset of stem cells- like cancer cells (CSCs), which represent &amp;lt;1 % of malignant breast tumors. Most importantly breast CSCs are highly resistant to radiation- and chemo-therapy. Such resistance could be attributed to the high expression of the enzyme, Aldehyde dehydrogenase I (ALDH1), which in recent years has been suggested to be a prognostic marker of breast cancer. However, the mechanism(s) of ALDH1's involvement in CSCs’ function and resistance to radiation/chemotherapy (oxidative stress) and its role in breast cancer progression are not known. Toxicity of most of the chemotherapeutic drugs is known to be via increased oxidative stress which generates lipid aldehydes such as 4-hydroxynonenal (HNE), a potent apoptotic agent. In CSCs the levels of ALDH1 are much higher than the normal breast cell as well as cancer cells. It is likely that the resistance of CSCs to chemotherapeutic drugs is due to increased levels of ALDH1 which is known to detoxify HNE generated by oxidative stress caused by chemotherapeutic drugs. Increased HNE could kill the cells by causing increased apoptosis. To test this hypothesis we inhibited ALDH1 in the tumoregenic human breast cancer cells, MDA-MB-468, by diethylaminobenzaldehyde (DEAB) and measured HNE-induced toxicity by evaluating the levels of protein-HNE adducts which, as previously demonstrated by us, increase in oxidation-induced apoptosis. ALDH1hi/CD44+ and ALDH1low/ CD44+ cells were sorted by flow cytometry using ALDEFLUO-FITC &amp; mouse anti-Human CD44-APC. The DEAB-treated cells when subjected to oxidative stress by H2O2, showed increased formation of protein -HNE adducts with a concomitant increase in apoptosis and decrease in cell viability. Furthermore, our results also displayed increased activation of the transcription factor, NF-kB which could be responsible for up-regulating the death genes leading to apoptosis. In addition, four specimens of human malignant breast cancer tissues and two of benign breast tumors were analyzed by double immunostaining. Compared to benign tumors, elevated levels of ALDH1 and CSC-like cells (high ALDH1/high CD44/lowCD24) were observed in the breast cancer tissues. Furthermore, levels of ALDH1 in these specimens appeared to be proportional to the grade of cancer. Our results thus suggest that disrupting ALDH1-mediated HNE detoxification in CSCs could be a novel preventive approach against breast cancer progression and metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 54.
Application of vasoactive and matrix-modifying drugs can improve polyplex delivery to tumors upon intravenous administration
Authors: Mikhail O. Durymanov, Alexey V. Yarutkin, Dmitry V. Bagrov, Dmitry V. Klinov, Alexander V. Kedrov, Nikolay K. Chemeris, Andrey A. Rosenkranz, Alexander S. Sobolev
Journal: Journal of Controlled Release (2016)
A Rare Case of Metastatic Clear Cell Carcinoma of the Müllerian System Originating From the Peritoneum Assessed by 18F-FDG PET/CT
Authors: Giorgio Treglia, Jessica Barizzi, Gaetano Paone, Luca Ceriani, Massimo Bongiovanni, Luca Giovanella
Journal: Clinical Nuclear Medicine (2014)

We describe a rare case of metastatic Müllerian tumor originating from the peritoneum assessed by F-FDG PET/CT. A 52-year-old female patient underwent F-FDG PET/CT for metabolic characterization of a right pelvic lesion. PET/CT revealed increased F-FDG uptake corresponding to a 3-cm lesion located behind the right anterior pelvic wall. Furthermore, increased F-FDG uptake in a right external iliac lymph node was detected. Based on these F-FDG PET/CT findings, the patient underwent resection of the pelvic lesion and the right external iliac lymph node. Histology demonstrated a clear cell carcinoma of the Müllerian system originating from the peritoneum with lymph nodal metastasis.
Intrathoracic Mass Simulated by Ectopic Kidney
Authors: MASAHIRO TOBA, KAZUKI FUKUCHI, KOHEI HAYASHIDA, YUTAKA TAKEDA, KAZUHITO FUKUSHIMA
Journal: Clinical Nuclear Medicine (2000)

A 66-year-old man was hospitalized for surgical repair of a right common iliac artery aneurysm. Dipyridamole stress Tl-201 myocardial imaging performed during a preoperative survey revealed a large mass with sustained radionuclide accumulation in the right thorax. Dynamic images with Tc-99m MAG3 clearly showed a right functioning intrathoracic kidney, a rare congenital anomaly.
MIF-CD74 GUIDED THERAPEUTIC STRATEGY FOR THE UPFRONT TREATMENT OF GBM PATIENTS WITH AN UNMETHYLATED MGMT PROMOTER
Authors: K. L. McDonald, W. Ha, H. Sevim
Journal: Neuro-Oncology (2014)

BACKGROUND: Promoter methylation of the DNA repair gene, MGMT is associated with improved treatment outcome for newly diagnosed glioblastoma (GBM) treated with standard chemoradiation. Currently, there are no universally effective systemic treatments available for patients with an unmethylated MGMT promoter or treatments for patients whose tumor recurs after primary treatment, irrespective of MGMT methylation status. We used SELDI-TOF MS to identify low molecular weight proteins associated with poor survival. We report a new therapeutic strategy with potential to overcome the drug resistance conferred by MGMT when applied as an adjunct therapy to the standard chemoradiation for patients. METHODS: We screened the low molecular weight proteome of patients' tumors, which were non-responsive to chemoradiotherapy (survival <12 months). Proteins of significant abundance in the non-responsive patients were purified, identified and validated in a larger cohort of GBM (n = 230). Inhibitors were sourced and efficacy of the drug was tested in patient derived tumor models. RESULTS: High expression of the inflammatory related protein Macrophage Inhibitory Factor (MIF) and its receptor, CD74 were found in patients who were non-responsive to chemoradiation. Heightened expression of both MIF and CD74 were identified in 57% of GBM (n = 230) and co-segregated with poor prognosis. CD74 forms a complex with CD44 at the cell surface. After MIF binds to the CD74/44 complex, Src is recruited. Src recruitment then initiates the activation of multiple pathways including Ras/MAPK and Akt resulting in tumor proliferation. Pro-angiogenic effects have also been attributed to this complex. Because of its involvement in tumorigenesis, inhibition of the MIF/CD74/CD44 complex with specific inhibitors in combination with chemoradiotherapy will likely abate the resistance to standard treatment and result in longer survival. Ibudilast (AV411; 3-isobutyryl-2-isopropylpyrazolo-[1,5-a] pyridine) is an anti-inflammatory drug that has been marketed for almost 20 years in Japan for treating asthma. Ibudilast inhibits the catalytic and chemo-functions of MIF. We tested a range of ibudilast concentrations in patient-derived cell lines and orthotopic patient-derived xenografts (PDX) models. When used in combination with TMZ, strong synergistic and inhibitory effects on tumor growth and improved overall survival were observed. CONCLUSIONS: Collectively, these data suggest that MIF/CD74 signaling may be an additional factor that contributes to TMZ resistance. Future studies will confirm whether the testing of GBM patients for increased expression of MIF/CD74 and subsequent treatment with a combination of ibudilast (or other small inhibitors of MIF/CD74) could be effectively used in our armamentarium against GBM. SECONDARY CATEGORY: Neuropathology & Tumor Biomarkers.
NINE-MONTH PRIMARY ENDPOINT RESULTS OF THE EVOLVE II QCA STUDY: A PROSPECTIVE, MULTICENTER TRIAL ASSESSING CLINICAL, ANGIOGRAPHIC, AND INTRAVASCULAR ULTRASOUND OUTCOMES WITH THE NOVEL PLATINUM-CHROMIUM ABLUMINALLY-COATED BIOABSORBABLE POLYMER SYNERGY EVEROLIMUS-ELUTING STENT IN DE NOVO CORONARY STENOSES
Authors: Ian Meredith, Warwick Jaffe, Seif El-Jack, Mark Webster, Douglas Scott, Shigeru Saito, Aaron Wong, John Ormiston, Dougal McClean, Huay Cheem Tan, Alan Whelan, Darren Walters, Dominic Allocco, Keith Dawkins
Journal: Journal of the American College of Cardiology (2015)
Abstract 1170: NFE2L2 gene mutation in Japanese lung cancer patients
Authors: Hidefumi Sasaki, Yu Hikosaka, Osamu Kawano, Katsuhiro Okuda, Satoru Moriyama, Motoki Yano, Yoshitaka Fujii
Journal: Cancer Research (2010)

Abstract Recently, the nuclear factor (erythroid derived 2)-like 2 (NFE2L2, former NRF2) gene mutation was identified in lung cancers. The constitutive activation of NFE2L2 in lung cancer cells promotes tumorigenicity. However, the correlation between NFE2L2 mutation status and clinico-pathological features of lung cancer was not well reported. We have investigated NFE2L2 gene mutation status in 263 surgically treated lung cancer cases from Nagoya City University Hospital. The presence or absence of NFE2L2 mutation was analyzed by direct sequences. EGFR mutations status was already investigated and reported. We detected 13 case (5.1%) of NFE2L2 mutation in our cohort, especially in male and squamous histology (p&amp;lt;0.0001). Total EGFR mutations were present in 78 patients (30.8%). The NFE2L2 mutation was exclusive with EGFR mutations. The NFE2L2 mutation occurred tendency towards more frequent in patients with advanced stages. The patient with NFE2L2 mutation (n=13, 8 were dead) was significantly worse prognosis than the patient with wild type NFE2L2 (n=250, 72 were dead) (Log-rank test, p=0.0035, Breslow-Gehan-Wilcoxon test; p=0.0030). In our study, NFE2L2 mutations might play a role in tumor prognosis of squamous cell carcinoma of the lung. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1170.
Abstract P6-06-32: 4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) locally advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)?
Authors: P Hadji, H Tesch, PA Fasching, DI Lueftner, W Janni, MP Lux, A Schneeweiss, T Decker, E Belleville, J Kreuzder, M Muth, D Wallwiener
Journal: Cancer Research (2013)

Abstract Introduction: BOLERO-2, a multi-national, double-blind, placebo-controlled, phase 3 study in postmenopausal women with HR+, HER2- advanced breast cancer (BC) progressing after non-steroidal aromatase inhibitors (NSAI), showed significant benefit in PFS with the addition of the mTOR inhibitor EVE to EXE compared to EXE alone (Baselga J 2012). The BOLERO-2 bone sub study indicated an influence of EVE on bone health after 6 and 12 weeks of treatment (Gnant M 2012). To further investigate the long term influence of mTOR inhibition on bone health, we initiated the phase IIIb, multi-center, open label study 4EVER for postmenopausal women with HR+ locally advanced or metastatic breast cancer treated with EVE +EXE. The primary endpoint is the overall response rate (ORR) after 6 months. Secondary endpoints include progression free survival after 6 and 12 months, ORR after 12 months, overall survival, quality of life, health utilities and health care resources. The exploratory objectives focus amongst others on the assessment of biomarkers of bone turnover. Methods: Main inclusion criteria were postmenopausal women with metastatic or locally advanced, ER+, HER2- breast cancer refractory to NSAI. Markers of bone turnover (P-I-NP, CTX, OPG, RANKL, vitamin D, FSH and estradiol) are being assessed at baseline and after 4, 12 and 24 weeks on treatment. Results: Baseline characteristics: 334 postmenopausal patients were screened and 297 were enrolled in 5 months. The hormone receptor assessment was performed in 71.0% from primary tumor and in 29% from the metastases (ER+/PgR+ 77.5%, ER+/PgR- 21.5%). The mean time since initial diagnosis was 9.2 years. Mean time since first recurrence/ metastasis was 48.1 months and mean time since most recent recurrence / metastasis 2.4 months. The stage at primary diagnosis was M0 74.2% and M1 22.0%. 68.7% of the patients had bone lesions. Most recent antineoplastic medications were in the adjuvant (24.8%), neoadjuvant (1.1%) and palliative setting (71.0%). 25.6% of the patients had one, 16.4% two and 57.9% three and more prior therapies in metastatic setting. The results of the baseline bone and hormone maker analysis for baseline and after 4, 12 and 24 weeks on treatment will be presented. Conclusion: This exploratory bone study will provide further insights into the influence of mTOR inhibition on bone turnover and overall bone health in women with advanced breast cancer. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-32.
Endoscopic submucosal dissection using the endoscopic operation robot
Authors: K. Kume, T. Kuroki, M. Shingai, M. Harada
Journal: Endoscopy (2012)

Technological developments to minimize invasiveness are important for next-generation endoscopes; however, this should be a consistent standard during medical treatment. Thus, we have extended our focus and developed the endoscopic operation robot (EOR) to provide robotized operational support for flexible endoscopes, which can be complicated to manipulate [1]. The EOR enables distal manipulation by controlling the flexible endoscope in four axes – specifically, vertical (up – down) and horizontal angulation (left – right) using one joystick, and rotation, scope extension, and retraction using a second joystick. This report presents a further development, a unit capable of distal manipulation of insulated tip (IT) knife extension and retraction ([Fig. 1]), and knife tip insertion and withdrawal, which is fitted on the EOR to allow carrying out endoscopic submucosal dissection (ESD) ([ Fig. 2 ]). A third joystick controls the IT-knife extension and retraction in the vertical axis as well as the insertion and withdrawal of the knife tip in the horizontal axis ([Fig. 3]).
THU0333 Ultrasonographic Characterization of the Shoulder Pain as Reason for Consultation in the Emergency Deparment of A Spanish Tertiary Center: Table 1
Authors: C. Guillen Astete, A.L. Boteanu, W.A. Sifuentes Giraldo, S. Garrote Corral, M. Llop Vilaltella, C. Bouruncle Alalua, A. Zea Mendoza
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The acute atraumatic shoulder pain is a frequent complaint in the emergency room. The power-Doppler ultrasonography (PDUS) is a useful tool in the evaluation of shoulder pathology in outpatients, but there are no previous studies in the emergency department. <h3>Objectives</h3> To determine the frequency and types of ultrasound findings in patients with acute shoulder pain who consult to the emergency department of a tertiary hospital. <h3>Methods</h3> This study included patients with acute atraumatic shoulder pain who consulted to the Unit of Rheumatology and Musculoskeletal Pathology of the Emergency Department of our center during the period from July to December 2013. A PDUS of affected shoulder was performed as part of the assessment protocol in these patients. The evaluated structures were the long head of the biceps tendon, subacromiodeltoid (SA) bursa, rotator cuff tendons, and glenohumeral (GH) and acromioclavicular (AC) joints. Results were expressed as measures of central tendency and dispersion, and proportions with confidence intervals (CI) of 95%. <h3>Results</h3> A total number of 116 pacientes were attended during this period, and PDUS was performed in 94 (81%). The mean age of patients was 58±4.9 years and 62.7% were female. PDUS identified 122 tendon injuries. Involvement of supraspinatus tendon was detected in 79.5% [CI 71.5-85.7], biceps tendon 26.2% [CI 19.2-34.67], subscapularis tendon 24.5% [CI 17.8-32.9], and infraspinatus tendon 9.8% [CI 6-19.6] (table). The age of the patients was not related to the presence of any particular type of lesion except for synovial effusion (SE) in the AC joint, whose prevalence was increased according to the quintile of patient age. <h3>Conclusions</h3> This is the first work that characterizes acute shoulder pain based on PDUS findings in emergency setting. The shoulder pain in outpatient clinics tends to be less intense, slowly progressive, and intermittent compared to that is assessed in the emergency department. Previous studies in inflammatory conditions demostrate a high frequency of SA bursa involvement, tenosynovitis and increased power-Doppler activity. In contrast, in our series the mechanical processes of the rotator cuff predominated and age does not seem to influence on PDUS findings unlike that is observed in the usual rheumatologic consultation. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5751
Abstract 1975: The mitochondrial pathway in baicalein and wogonin-induced apoptosis in human colorectal cancer cells
Authors: Chong-Zhi Wang, Jacqueline Somogyi, Chun-Su Yuan
Journal: Cancer Research (2012)

Abstract Treating colorectal cancer patients commonly involves several conventional modalities, including surgery, radiation, and chemotherapy. The complexity of colorectal cancer, however, requires additional alternatives to improve the therapeutic efficacy of conventional treatment and the quality of life of cancer patients. Medicinal botanicals have recently gained attention as additions to colorectal cancer management. Numerous effective anticancer drugs have been developed from botanicals, and identifying new herbal sources for ideal chemoprevention remains essential to advance the treatment of colorectal cancer. Scutellaria baicalensis extract (SbE) has chemopreventive effects on several cancers. Baicalin, a major constituent of SbE, also may have the negative effect of decreasing the anti-tumor potential of SbE. In this study, we prepared a baicalin knockout fraction (BKF) of SbE and evaluated its antiproliferative activity and mechanism of action. The constituents of BKF, baicalin fraction (BF), and SbE were quantified by HPLC. We then used an MTS assay to determine the effects of BKF, BF, SbE, and the representative flavonoids on the proliferation of human colorectal cancer cells (HCT-116 and HT-29). Cell cycle, cyclin A expression and cell apoptosis were assayed by flow cytometry. Apoptosis-related gene expression was visualized by quantitative real-time polymerase chain reaction (PCR), and mitochondrial membrane potential was estimated after staining with JC-1. HPLC analysis showed that BKF contained baicalein and wogonin; BF contained only baicalin. SbE had little antiproliferative effect on cancer cells, even increasing cancer cell growth at certain concentrations. BF increased cancer cell growth. BKF showed potent antiproliferative effects on cancer cells. BKF arrested cells in the S and G2/M phases, increased expression of cyclin A, and significantly induced cell apoptosis. Multiple genes in the mitochondrial pathway were involved in BKF-induced apoptosis, and subsequent cellular functional analysis validated the pathway. These results suggest that knocking out baicalin from SbE produces a BKF that significantly inhibits the growth of colorectal cancer cells. The active anticancer compounds in SbE are flavonoid aglycons, baicalein and wogonin, and the mitochondrial apoptotic pathway is part of baicalein and wogonin-induced apoptosis. (This work was supported in part by the NIH/NCCAM grants AT004418 and AT005362). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1975. doi:1538-7445.AM2012-1975